Expanded access to a heart device
This trial provides access to a device called the Atrial Flow Regulator, which helps manage heart conditions by regulating blood flow. It may be an option for patients who have limited alternatives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a heart condition that the device is designed to treat.
- You must not have other treatment options available.
- You must be able to participate in ongoing monitoring and follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with chronic heart failure to see how well an implanted device (called the Occlutech AFR) works and whether it is safe over time. It may help doctors better understand who benefits and how to manage treatment safely.
This study looks at how well the Occlutech AFR device works for people with a failing Fontan circulation. It is only open to those who already received the device through a special early-access program.
This trial tests a new device to help doctors safely enter the left side of your heart during a procedure called ablation. If you are already scheduled for an ablation or a combined ablation and left atrial appendage closure, this study may be an option.
This trial tests a new device used during open-heart surgery to treat atrial fibrillation (AFib) by delivering tiny, fast electrical pulses to the heart tissue. It is for people who are already having heart surgery and want to also treat their AFib at the same time.
This trial tests a new catheter system to treat atrial fibrillation (AF) by creating small scars in the heart to block faulty signals. It may help people with symptoms that continue despite medication and who are scheduled for a standard ablation procedure.
This study tests advanced technology to improve how atrial fibrillation (AFib) is treated with a heart ablation procedure. It may help patients who are already advised to have AFib ablation by seeing how well the approach works in real clinical practice.